Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

IND.224 - A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of Patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases - was centrally activated on November 23, 2016.

The primary objective of this trial is to determine the intracranial objective response rate to concurrent dabrafenib and trametinib with stereotactic radiation in patients with BRAF mutation-positive malignant melanoma and brain metastases.

Secondary objectives are:
  • Extra-cranial objective response rate and overall ORR;
  • Duration of response;
  • Intracranial and overall progression-free survival;
  • Overall Survival; and,
  • To evaluate the safety and tolerability of the regimen using the CTCAE v.4.
Interested investigators should contact Linda Hagerman, Study Coordinator, at lhagerman@ctg.queensu.ca.